Skip to main content

Folate

Folate (vitamin B9) is a water-soluble B vitamin essential for one-carbon metabolism, DNA synthesis, amino-acid homeostasis, and epigenetic regulation.[1][2][3] It is the primary carrier of one-carbon units required for de novo synthesis of purines and thymidylate (for DNA replication) and for remethylation of homocysteine to methionine, generating S-adenosylmethionine (SAM), the universal methyl donor.[1][4] Folate deficiency remains clinically important despite mandatory folic-acid fortification, particularly in pregnancy, alcohol use disorder, and patients on certain medications.

For the reconstructive urologist and urogynecologist, folate matters in three core scenarios: (1) preconception counseling in any reproductive-age patient undergoing reconstruction with downstream pregnancy potential, (2) adult congenital / spina bifida transitional-urology patients (NTD pathology context, methotrexate / valproate exposure, possible familial NTD history), and (3) drug-induced deficiency in patients on methotrexate, anticonvulsants, sulfasalazine (IBD), trimethoprim chronic suppression for rUTI, or chronic alcohol use.

Biochemistry and Metabolism​

"Folate" refers to the naturally occurring reduced forms of vitamin B9 (pteroylglutamates); folic acid is the synthetic, oxidized form used in supplements and fortified foods. Folic acid has approximately 70% higher bioavailability than food folate.[5] After absorption in the proximal jejunum, dietary folate is converted to 5-methyltetrahydrofolate (5-MTHF), the predominant circulating form, which donates its methyl group to homocysteine via the B12-dependent enzyme methionine synthase.[2][3]

Two critical metabolic outputs depend on folate:

  • Nucleotide synthesis — 5,10-methylenetetrahydrofolate is required by thymidylate synthase for conversion of dUMP to dTMP. Folate deficiency causes uracil misincorporation into DNA, leading to strand breaks and impaired DNA repair.[1][4]
  • Methylation reactions — 5-MTHF feeds the methionine cycle to generate SAM, which methylates DNA, histones, proteins, and lipids. Disruption leads to hyperhomocysteinemia and aberrant DNA methylation.[3][6]

Dietary Sources and Requirements​

Folate occurs naturally in dark green leafy vegetables, legumes, citrus fruits, and liver.[5][7] The RDA for adults is 400 μg dietary folate equivalents (DFE)/day, rising to 600 μg DFE/day in pregnancy.[8][9] The tolerable upper intake level (UL) for folic acid from supplements and fortified foods is 1,000 μg/day, set primarily to avoid masking vitamin B12 deficiency.[8][7]

Since 1998, the US has mandated folic-acid fortification of enriched cereal grain products, which has substantially reduced the prevalence of both folate deficiency and neural tube defects.[8] NHANES 2007–2018 data show that median natural-food folate intake (222 μg DFE/day) remains below the EAR of 320 μg DFE/day, underscoring the continued importance of fortification; only ~ 2% of adults exceed the UL.[9]

Assessment of Folate Status​

  • Serum folate — Reflects recent intake; levels < 3 ng/mL (6.8 nmol/L) indicate deficiency.[5][10]
  • Red blood cell (RBC) folate — Reflects body stores over the preceding 3–4 months (analogous to HbA1c for glucose); levels < 140 ng/mL (305 nmol/L) indicate deficiency. Preferred marker when feasible.[5][10]
  • Homocysteine — Elevated in both folate and B12 deficiency; sensitive but nonspecific. Unlike B12 deficiency, folate deficiency does not elevate methylmalonic acid (MMA) — this is the key biochemical differentiator.[11][12]

Causes of Deficiency​

CategoryExamples
Dietary insufficiencyLow intake of vegetables / legumes, alcohol use disorder, poverty, restrictive diets
MalabsorptionCeliac disease, IBD, tropical sprue, short bowel syndrome
Increased demandPregnancy, lactation, hemolytic anemias, exfoliative dermatitis, rapid growth (adolescence)
MedicationsMethotrexate, phenytoin, carbamazepine, valproate, sulfasalazine, trimethoprim, oral contraceptives, alcohol
GeneticMTHFR C677T homozygosity (reduced enzyme activity)

Notably, body stores of folate are limited (5–20 mg), and deficiency can develop within 2–4 months of inadequate intake — much faster than B12 deficiency (3–5 years).[10]

Clinical Manifestations​

Hematologic — Megaloblastic anemia identical to that of B12 deficiency: macrocytosis (MCV often > 110 fL), oval macrocytes, hypersegmented neutrophils, pancytopenia in severe cases.[11][12] Unlike B12 deficiency, folate deficiency does not cause subacute combined degeneration, though some evidence suggests folate deficiency may contribute to peripheral neuropathy and neuropsychiatric symptoms in certain patients.[11][13]

Pregnancy complications — Folate deficiency is the most common cause of megaloblastic anemia in pregnancy in the US.[14] Beyond anemia, inadequate folate is strongly linked to neural tube defects (NTDs), and may contribute to preeclampsia and other adverse outcomes through hyperhomocysteinemia.[15][16]

Neural Tube Defect Prevention​

This is the most impactful clinical application of folate. The USPSTF gives an A recommendation for all persons planning or capable of pregnancy to take 0.4–0.8 mg (400–800 μg) of folic acid daily, beginning at least 1 month before conception and continuing through 12 weeks of gestation.[17][7][18] Key evidence:

  • Periconceptional folic acid reduces first occurrence of NTDs by 50–70% and recurrence by 72% (MRC Vitamin Study: RR 0.28, 95% CI 0.12–0.71).[19]
  • Women at high risk (prior NTD-affected pregnancy, personal NTD, affected partner, certain anticonvulsants) should take 4 mg (4,000 μg) daily, starting 3 months before conception.[19]
  • US mandatory fortification has been linked to a 19% decrease in all NTDs (23% for spina bifida, 11% for anencephaly).[19]
  • Despite fortification, ~ 75% of nonpregnant women of childbearing age do not consume the recommended daily intake of folic acid for NTD prevention from diet alone.[7]

Neural tube closure occurs by day 28 of gestation — often before pregnancy recognition — making preconceptional supplementation essential.[19]

MTHFR C677T Polymorphism​

The methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism is the most clinically relevant genetic variant affecting folate metabolism. Homozygosity (TT genotype) occurs in 5–15% of Western populations and produces a thermolabile enzyme with ~ 30% reduced activity, lowering circulating 5-MTHF and raising homocysteine.[12][20][21] Meta-analysis shows TT individuals have 13% lower serum folate and 16% lower RBC folate vs CC.[22]

The TT genotype is associated with increased risk of NTDs and hypertension; adequate folate intake largely mitigates these risks.[20][21] Routine MTHFR genotyping is not recommended for the general population — the clinical implications are addressed by ensuring adequate folate intake.[23]

Folate and Cardiovascular Disease​

Folic acid lowers homocysteine by approximately 25%.[24] Despite strong observational associations between elevated homocysteine and CVD, large RCTs have been largely negative for major cardiovascular events:

  • HOPE-2, NORVIT, WENBIT — homocysteine reduction without cardiovascular benefit.[25]
  • Meta-analysis of 30 RCTs (82,334 participants) — 10% reduction in stroke (RR 0.90, 95% CI 0.84–0.96) and 4% reduction in overall CVD (RR 0.96, 0.92–0.99), with greater benefit in lower-baseline-folate populations.[26]

The AHA/ASA 2021 stroke-prevention guideline notes the evidence remains inconsistent; routine supplementation for secondary stroke prevention is not firmly established.[27]

Folate and Cancer​

The folate-cancer relationship — particularly colorectal cancer (CRC) — is complex and follows a dual-modulator hypothesis: adequate folate protects normal mucosa from carcinogenesis, but excess folate may promote growth of pre-existing neoplastic foci.[28][29]

  • Observational — Higher total folate intake associates with a 12–16% reduction in CRC risk (RR 0.84, 95% CI 0.80–0.90), with stronger protection among alcohol consumers.[28][30][31]
  • Supplementation trials — Folic acid has not reduced adenoma recurrence in RCTs and may increase risk of advanced adenomas and serrated polyps.[29]
  • B-PROOF trial — Combined folic acid (400 μg) + B12 supplementation was associated with increased overall cancer risk (HR 1.25) and CRC risk (HR 1.77) over long-term follow-up.[32]

The AGA Clinical Practice Update concludes that while dietary folate appears protective, folic acid supplementation should not be recommended specifically for CRC chemoprevention.[29]

Drug Interactions​

Several drug-folate interactions warrant clinical attention:[33][34][13][35]

  • Methotrexate — Inhibits dihydrofolate reductase (DHFR), blocking conversion of dihydrofolate to tetrahydrofolate. In rheumatologic use, folic acid 1 mg daily (except on methotrexate day) reduces side effects without compromising efficacy. In oncologic use, folic acid coadministration decreases methotrexate's antineoplastic effectiveness; leucovorin (folinic acid) rescue is used instead for high-dose protocols.[36]
  • Anticonvulsants — Phenytoin, carbamazepine, phenobarbital, primidone increase hepatic folate metabolism and impair intestinal absorption, lowering serum folate. Conversely, folic acid supplementation can antagonize the anticonvulsant action of phenytoin, potentially requiring dose adjustment.[33][34][35]
  • Valproate — Associated with both folate deficiency and teratogenicity (NTD risk); mechanism may involve disruption of the methionine cycle.[37]
  • Alcohol — Inhibits intestinal absorption, hepatic uptake, and metabolic utilization of folate; the most common cause of folate deficiency in developed countries.[33]

Masking of Vitamin B12 Deficiency — A Critical Safety Concern​

The FDA label carries a specific warning: folic acid doses > 0.1 mg daily may obscure pernicious anemia by correcting the hematologic manifestations (megaloblastic anemia) while allowing neurologic damage to progress unchecked.[35][34] This "masking" effect occurs because exogenous folic acid bypasses the methyl trap caused by B12 deficiency, restoring thymidylate synthesis and normalizing erythropoiesis without addressing the impaired methylation reactions responsible for demyelination.[38][39]

NHANES data suggest that among individuals with low B12 status, those with high serum folate have worse cognitive impairment (OR 5.0) and more severe anemia (OR 4.9) compared with those with normal folate — a pattern not seen before mandatory fortification.[40] This has led to the hypothesis that excess folic acid may actively deplete holotranscobalamin (the metabolically active B12 fraction), worsening functional B12 deficiency.[38][41]

Always exclude B12 deficiency before initiating folic acid therapy for megaloblastic anemia. The 1,000 μg/day UL for folic acid was set explicitly to mitigate this masking risk.[8][42][43]

Treatment of Folate Deficiency​

  • Oral folic acid 1–5 mg daily for 4 months to replete stores, followed by maintenance at 0.4 mg daily (0.8 mg in pregnancy / lactation).[12][35]
  • Resistant cases or those with malabsorption may require higher doses.[35]
  • Always rule out concurrent B12 deficiency before treatment — folic acid alone will correct the anemia but not prevent neurologic deterioration.[11][35]
  • In pregnancy, the usual therapeutic dose is 1 mg daily; response is typically rapid with reticulocytosis within days.[14]

Reconstructive Relevance​

1. Preconception Counseling Is the Reconstructive Surgeon's Job​

Any reproductive-age patient scheduled for major reconstruction with downstream pregnancy potential — urogynecology (prolapse repair, MUS, fistula repair, BMG urethroplasty), gender-affirming reconstruction with retained or transposed reproductive organs, adult-congenital reconstruction with fertility preservation, lower-tract reconstruction after IBD or pelvic injury — should be on 400–800 μg folic acid daily preconception per USPSTF A recommendation. The "I'll defer to OB" reflex misses the window: neural tube closure is complete by day 28, often before pregnancy is recognized.

2. Adult Congenital / Spina Bifida Transitional Urology​

The transitional-urology population — adult patients with spina bifida or other NTDs in long-term care — carries additional folate-relevant considerations:

  • High-risk preconception dose (4 mg daily, 3 months pre-conception) in patients with personal NTD or affected partner.
  • Anticonvulsant interactions — phenytoin, carbamazepine, valproate are common in this population; all lower folate and increase NTD risk in subsequent pregnancies. Valproate is the highest-risk.
  • Methotrexate exposure — in associated rheumatologic / IBD conditions, mandates folic-acid coadministration AND reliable contraception.

3. Drug-Induced Folate Deficiency in Reconstructive Patients​

  • Methotrexate for autoimmune disease (RA, psoriatic arthritis, IBD, BPS/IC adjunct) — add folic acid 1 mg daily except on MTX day; verify before any elective reconstruction.
  • Sulfasalazine in IBD patients undergoing reconstruction (urinary diversion, fistula repair) — chronic users develop deficiency.
  • Trimethoprim chronic suppression for rUTI — competitive DHFR inhibitor; long-term use can lower folate. Monitor and supplement in extended courses.
  • Anticonvulsants in NLUTD / spina bifida patients undergoing augmentation, channels, or sphincter procedures — verify folate status preoperatively.
  • Alcohol use disorder in trauma reconstruction patients — universal supplementation pending recovery.

4. Post-Bariatric Reconstruction​

Folate is absorbed in the proximal jejunum, so RYGB / BPD-DS impair absorption. Standard post-bariatric monitoring includes baseline + annual folate alongside B12, iron, and B-complex screening.[44]

5. The B12-Masking Trap in Diversion Patients​

Patients with ileal-bowel reconstruction (conduit, neobladder, augmentation) carry elevated B12-deficiency risk. Do not initiate empiric folic acid for unexplained macrocytic anemia in this population without checking B12 first — folic acid will normalize the hematology while subacute combined degeneration progresses silently. Cross-reference: Vitamin B12.

See Also​

References​

1. Stover PJ, Garza C. "Bringing Individuality to Public Health Recommendations." The Journal of Nutrition. 2002;132(8 Suppl):2476S–2480S. doi:10.1093/jn/132.8.2476S

2. Balashova OA, Visina O, Borodinsky LN. "Folate action in nervous system development and disease." Developmental Neurobiology. 2018;78(4):391–402. doi:10.1002/dneu.22579

3. Ducker GS, Rabinowitz JD. "One-Carbon Metabolism in Health and Disease." Cell Metabolism. 2017;25(1):27–42. doi:10.1016/j.cmet.2016.08.009

4. Field MS, Kamynina E, Agunloye OC, et al. "Nuclear Enrichment of Folate Cofactors and Methylenetetrahydrofolate Dehydrogenase 1 (MTHFD1) Protect De Novo Thymidylate Biosynthesis During Folate Deficiency." The Journal of Biological Chemistry. 2014;289(43):29642–29650. doi:10.1074/jbc.M114.599589

5. Centeno Tablante E, Pachón H, Guetterman HM, Finkelstein JL. "Fortification of Wheat and Maize Flour With Folic Acid for Population Health Outcomes." Cochrane Database of Systematic Reviews. 2019;7:CD012150. doi:10.1002/14651858.CD012150.pub2

6. Copp AJ, Stanier P, Greene ND. "Neural Tube Defects: Recent Advances, Unsolved Questions, and Controversies." The Lancet Neurology. 2013;12(8):799–810. doi:10.1016/S1474-4422(13)70110-8

7. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. "Folic Acid Supplementation for the Prevention of Neural Tube Defects: US Preventive Services Task Force Recommendation Statement." JAMA. 2017;317(2):183–189. doi:10.1001/jama.2016.19438

8. Allen LH. "Micronutrients — Assessment, Requirements, Deficiencies, and Interventions." The New England Journal of Medicine. 2025;392(10):1006–1016. doi:10.1056/NEJMra2314150

9. Zhou Y, Wang A, Yeung LF, et al. "Folate and Vitamin B12 Usual Intake and Biomarker Status by Intake Source in United States Adults Aged ≥ 19 Y: NHANES 2007–2018." The American Journal of Clinical Nutrition. 2023;118(1):241–254. doi:10.1016/j.ajcnut.2023.05.016

10. De Bruyn E, Gulbis B, Cotton F. "Serum and red blood cell folate testing for folate deficiency: new features?" European Journal of Haematology. 2014;92(4):354–359. doi:10.1111/ejh.12237

11. Green R, Datta Mitra A. "Megaloblastic Anemias: Nutritional and Other Causes." The Medical Clinics of North America. 2017;101(2):297–317. doi:10.1016/j.mcna.2016.09.013

12. Provan D, Weatherall D. "Red Cells II: Acquired Anaemias and Polycythaemia." Lancet. 2000;355(9211):1260–1268. doi:10.1016/S0140-6736(00)02099-7

13. Gwathmey KG, Grogan J. "Nutritional neuropathies." Muscle & Nerve. 2020;62(1):13–29. doi:10.1002/mus.26783

14. Committee on Practice Bulletins—Obstetrics. "Anemia in Pregnancy: ACOG Practice Bulletin, Number 233." Obstetrics and Gynecology. 2021;138(2):e55–e64. doi:10.1097/AOG.0000000000004477

15. De-Regil LM, Peña-Rosas JP, Fernández-Gaxiola AC, Rayco-Solon P. "Effects and Safety of Periconceptional Oral Folate Supplementation for Preventing Birth Defects." Cochrane Database of Systematic Reviews. 2015;(12):CD007950. doi:10.1002/14651858.CD007950.pub3

16. Iskandar BJ, Finnell RH. "Spina Bifida." The New England Journal of Medicine. 2022;387(5):444–450. doi:10.1056/NEJMra2116032

17. Viswanathan M, Urrutia RP, Hudson KN, Middleton JC, Kahwati LC. "Folic Acid Supplementation to Prevent Neural Tube Defects: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force." JAMA. 2023;330(5):460–466. doi:10.1001/jama.2023.9864

18. US Preventive Services Task Force, Barry MJ, Nicholson WK, et al. "Folic Acid Supplementation to Prevent Neural Tube Defects: US Preventive Services Task Force Reaffirmation Recommendation Statement." JAMA. 2023;330(5):454–459. doi:10.1001/jama.2023.12876

19. Committee on Practice Bulletins—Obstetrics. "Practice Bulletin No. 187: Neural Tube Defects." Obstetrics and Gynecology. 2017;130(6):e279–e290. doi:10.1097/AOG.0000000000002412

20. Reilly R, McNulty H, Pentieva K, Strain JJ, Ward M. "MTHFR 677TT Genotype and Disease Risk: Is There a Modulating Role for B-Vitamins?" The Proceedings of the Nutrition Society. 2014;73(1):47–56. doi:10.1017/S0029665113003613

21. Bailey LB, Gregory JF. "Polymorphisms of Methylenetetrahydrofolate Reductase and Other Enzymes." The Journal of Nutrition. 1999;129(5):919–922. doi:10.1093/jn/129.5.919

22. Tsang BL, Devine OJ, Cordero AM, et al. "Assessing the Association Between the MTHFR 677C>T Polymorphism and Blood Folate Concentrations: A Systematic Review and Meta-Analysis." The American Journal of Clinical Nutrition. 2015;101(6):1286–1294. doi:10.3945/ajcn.114.099994

23. Mazokopakis EE, Papadomanolaki MG, Papadakis JA. "Association of MTHFR Gene Polymorphisms With Serum Folate, Cobalamin and Homocysteine Concentrations in Greek Adults." Scandinavian Journal of Clinical and Laboratory Investigation. 2023;83(2):69–73. doi:10.1080/00365513.2023.2167232

24. Kaye AD, Jeha GM, Pham AD, et al. "Folic Acid Supplementation in Patients With Elevated Homocysteine Levels." Advances in Therapy. 2020;37(10):4149–4164. doi:10.1007/s12325-020-01474-z

25. Freeman AM, Morris PB, Aspry K, et al. "A Clinician's Guide for Trending Cardiovascular Nutrition Controversies: Part II." Journal of the American College of Cardiology. 2018;72(5):553–568. doi:10.1016/j.jacc.2018.05.030

26. Li Y, Huang T, Zheng Y, et al. "Folic Acid Supplementation and the Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials." Journal of the American Heart Association. 2016;5(8):e003768. doi:10.1161/JAHA.116.003768

27. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. "2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack." Stroke. 2021;52(7):e364–e467. doi:10.1161/STR.0000000000000375

28. Li T, Yin L, Li Y, et al. "Folate Exposures and Risk of Colorectal Cancer: An Umbrella Review of Meta-Analyses of Observational Studies and Randomised Controlled Trials." BMJ Open. 2025;15(11):e103637. doi:10.1136/bmjopen-2025-103637

29. Liang PS, Shaukat A, Crockett SD. "AGA Clinical Practice Update on Chemoprevention for Colorectal Neoplasia: Expert Review." Clinical Gastroenterology and Hepatology. 2021;19(7):1327–1336. doi:10.1016/j.cgh.2021.02.014

30. Fu H, He J, Li C, Deng Z, Chang H. "Folate Intake and Risk of Colorectal Cancer: A Systematic Review and Up-to-Date Meta-Analysis of Prospective Studies." European Journal of Cancer Prevention. 2023;32(2):103–112. doi:10.1097/CEJ.0000000000000744

31. Khalighi Sikaroudi M, Soltani S, Kolahdouz-Mohammadi R, et al. "The Association Between Dietary Folate Intake and Risk of Colorectal Cancer Incidence: A Systematic Review and Dose-Response Meta-Analysis of Cohort Studies." Heliyon. 2024;10(13):e33564. doi:10.1016/j.heliyon.2024.e33564

32. Oliai Araghi S, Kiefte-de Jong JC, van Dijk SC, et al. "Folic Acid and Vitamin B12 Supplementation and the Risk of Cancer: Long-Term Follow-Up of the B-PROOF Trial." Cancer Epidemiology, Biomarkers & Prevention. 2019;28(2):275–282. doi:10.1158/1055-9965.EPI-17-1198

33. Hesdorffer CS, Longo DL. "Drug-Induced Megaloblastic Anemia." The New England Journal of Medicine. 2015;373(17):1649–1658. doi:10.1056/NEJMra1508861

34. Lambie DG, Johnson RH. "Drugs and Folate Metabolism." Drugs. 1985;30(2):145–155. doi:10.2165/00003495-198530020-00003

35. Food and Drug Administration. "Folic acid." Label updated 2024-10-28.

36. Food and Drug Administration. "Methotrexate." Label updated 2025-09-22.

37. Alonso-Aperte E, Varela-Moreiras G. "Drugs-Nutrient Interactions: A Potential Problem During Adolescence." European Journal of Clinical Nutrition. 2000;54 Suppl 1:S69–S74.

38. Selhub J, Miller JW, Troen AM, Mason JB, Jacques PF. "Perspective: The High-Folate-Low-Vitamin B-12 Interaction Is a Novel Cause of Vitamin B-12 Depletion With a Specific Etiology — a Hypothesis." Advances in Nutrition. 2022;13(1):16–33. doi:10.1093/advances/nmab106

39. Rashid S, Meier V, Patrick H. "Review of Vitamin B12 deficiency in pregnancy: a diagnosis not to miss as veganism and vegetarianism become more prevalent." European Journal of Haematology. 2021;106(4):450–455. doi:10.1111/ejh.13571

40. Selhub J, Morris MS, Jacques PF, Rosenberg IH. "Folate-Vitamin B-12 Interaction in Relation to Cognitive Impairment, Anemia, and Biochemical Indicators of Vitamin B-12 Deficiency." The American Journal of Clinical Nutrition. 2009;89(2):702S–706S. doi:10.3945/ajcn.2008.26947C

41. Miller JW, Smith A, Troen AM, et al. "Excess Folic Acid and Vitamin B12 Deficiency: Clinical Implications?" Food and Nutrition Bulletin. 2024;45(1_suppl):S67–S72. doi:10.1177/03795721241229503

42. Castillo LF, Pelletier CM, Heyden KE, Field MS. "New Insights Into Folate-Vitamin B12 Interactions." Annual Review of Nutrition. 2025. doi:10.1146/annurev-nutr-120524-043056

43. Reynolds EH, Sobczyńska-Malefora A, Green R. "Fortification, Folate and Vitamin B12 Balance, and the Nervous System. Is Folic Acid Excess Potentially Harmful?" European Journal of Clinical Nutrition. 2025. doi:10.1038/s41430-025-01652-8

44. Mechanick JI, Apovian C, Brethauer S, et al. "Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures — 2019 Update." Obesity. 2020;28(4):O1–O58. doi:10.1002/oby.22719